Kevin Stankiewicz, CNBC

Kevin Stankiewicz


New York, NY, United States

Contact Kevin

Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.

Start free trial

  • Unknown
  • CNBC
  • The Columbus Dispatch
  • The Palm Beach Post
  • The Daily Herald
  • Providence Journal
  • GoErie
  • ThisWeekNEWS

Past articles by Kevin:

Oracle buddies up with Microsoft. Plus our take on Salesforce and Meta news

Microsoft (MSFT) and Oracle (ORCL) announce a product with the potential to benefit both stocks. Also: Salesforce is hiring, and Meta denies a WhatsApp report. → Read More

Oil prices are at 10-month highs. Here's what Cramer thinks it means for two energy stocks

West Texas Intermediate crude, the U.S. oil benchmark, has jumped 32% since its lows of the summer, to nearly $89 a barrel. → Read More

Jim Cramer says 'watch Ford as a barometer' of potential United Auto Workers strike risk

Ford Motor's (F) stock may offer clues into Wall Street's current attitude toward potential strikes by the United Auto Workers union, CNBC's Jim Cramer said. → Read More

Jim Cramer sees 'green shoot' in stock market reaction to this secondary stock sale

The market reaction to a $300 million secondary stock offering from Dutch Bros (BROS) is an encouraging sign, CNBC's Jim Cramer said. → Read More

This health-care stock is set to complete another spin-off. Here's what it means for our position in the stock

Medical equipment giant Danaher (DHR) will officially separate from its environmental-and-applied solutions segment later this month. → Read More

The huge rally in Salesforce's stock isn't over: Here's how high we see it going

"Even as the stock has rallied, it deserves to go much higher," says Jim Cramer. → Read More

AI in focus: Here's what to look for when Salesforce and Broadcom report earnings

When these two tech firms release earnings, Wall Street will be looking to see if their respective bets on artificial intelligence are starting to pay off. → Read More

Jim Cramer says this surging cybersecurity is gaining market share and proving doubters wrong

Palo Alto Networks is a compelling stock to own as it gains share in the increasingly important cybersecurity market, CNBC's Jim Cramer said. → Read More

Salesforce raises prices for the first time in 7 years. What it means for the stock

Indeed, Tuesday's news underscores co-founder and CEO Marc Benioff's commitment to growing profits at Salesforce. → Read More

We know A.I. is big for Nvidia. But new estimates of just how big are staggering

Goldman Sachs put out its medium-term estimate of Nvidia's generative artificial intelligence opportunity. → Read More

Two health-care stocks are in the headlines. How the news impacts our investments

Positive developments for one of Eli Lilly's (LLY) rivals in Alzheimer's treatments are good news for the Club holding. But, Humana catches a downgrade. → Read More

History shows Wall Street can sustain its first half advance. How Jim Cramer is playing it

The stock market's strong first-half performance may be a tough act to follow. → Read More

Here are our 4 best stocks — and 4 worst stocks — of the first half of 2023

Tech stocks were the standout performers in the first half of 2023, powering Wall Street — and the Club's portfolio. → Read More

Apple's all-time high is not the only one in our portfolio. Plus, why Nvidia is rebounding

The Investing Club holds its "Morning Meeting" every weekday at 10:20 a.m. ET. → Read More

Wall Street shows ongoing frustration with an entertainment giant, sees gains ahead for 2 retailers

Wall Street showed ongoing — and understandable — frustration with Walt Disney's (DIS) lackluster share-price performance. → Read More

Nvidia knocks down concern over AI chip exports to China. The reason is why we own the stock

Nvidia (NVDA) on Wednesday reassured investors that potential export restrictions on chips wouldn't hurt the semiconductor firm's bottom line. → Read More

Here's a list of weight-loss drugs in development and awaiting approval to take on Ozempic

After a busy few days for the diabetes-and-obesity drug industry, our conviction in Eli Lilly (LLY) remains intact. → Read More

New data fortifies Eli Lilly's standing in the burgeoning market for weight-loss drugs

The drugmaker's oral obesity pill demonstrated impressive efficacy in a mid-stage study. → Read More

Be patient with this red-hot tech stock, as it soars to new all-time high

The Investing Club holds its "Morning Meeting" every weekday at 10:20 a.m. ET. → Read More

Stocks fall, but Jim Cramer says its not time to buy yet

The Investing Club holds its "Morning Meeting" every weekday at 10:20 a.m. ET. → Read More